Human Therapies as a Successful Liaison between Chemistry and Biology  by Baeuerle, Patrick A. & Murry, Jerry A.
Chemistry & Biology
PerspectiveHuman Therapies as a Successful Liaison
between Chemistry and BiologyPatrick A. Baeuerle1 and Jerry A. Murry2,*
1Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany
2Amgen, Inc., Process Development, Thousand Oaks, CA 91320, USA
*Correspondence: jmurry@amgen.com
http://dx.doi.org/10.1016/j.chembiol.2014.08.014
The development of novel therapies is arguably one of the most important roles of modern chemistry and
biology. Here, we shed light on a particular class of human therapies in which synthetic chemical entities
are attached to expressed biologicals (proteins) with the goal to enhance clinical activity. We focus our dis-
cussion on three key categories of these derivatized biologicals: proteins conjugated with biologically inert
molecules, proteins conjugated with biologically active small molecules and peptides (e.g., antibody drug
conjugates [ADCs]), and proteins conjugated with radio isotopes. Overall, it is apparent by the impact on
clinical activity as well as the commercial success that chemical modification of recombinant proteins is
becoming of increasing importance. Therefore, we argue that deeper understanding of the chemical reac-
tions between large proteinaceous molecules and small molecule reagents will allow for more precise and
elegant solutions to existing limitations in this field.Human therapeutics are divided into small molecules (<103 Da
molecular weight) and large molecules; cell-derived biological
drugs, biologics (mostly proteins), have molecular weights
ranging from 104 to106 Da. Traditionally, they have been consid-
ered to fall under the purview of two separate industries—the
pharmaceutical, with interest in small molecules, and bio-
technology, with interests in biologics—as their discovery and
development paths use fundamentally different techniques.
Small molecule therapeutics are typically derived from high-
throughput screening of chemical compound libraries followed
by medicinal chemistry and target structure-guided lead optimi-
zation. Biological drugs are initially derived from living organisms
and drug leads generated by employing biotechnology and re-
combinant DNA technology. The huge success of therapeutic
proteins, mostly monoclonal antibodies (mAbs) and hormones,
in the last two decades raised an enormous interest in biologics
at pharmaceutical companies that traditionally focused on
small molecule drug discovery and development. Protein-based
drugs are the largest and fastest growing class of therapeutics
with $165 billion (B) (of $754B total) in world-wide sales in
2013. Moreover, 6 of the 10 top-selling therapeutics in 2013
were proteins, namely, adalimumab (Humira, $11.0B), etaner-
cept (Enbrel, $8.8B), infliximab (Remicade, $8.4B), insulin glar-
gine recombinant (Lantus, $7.6B), rituximab (Rituxan and Mab-
Thera, $7.5B), bevacizumab (Avastin, $6.8B), and trastuzumab
(Herceptin, $6.6B). By 2020, it is projected that protein-based
therapeutics will reach >$300B in worldwide sales, with the
anti-TNF-a antibody adalilumab (Humira) as the single largest
selling drug with more than $12B in annual sales in 2018 (Eval-
uate Pharma 2014 Outlook, http://www.evaluategroup.com/
public/Reports/EvaluatePharma-World-Preview-2014.aspx). As
a consequence, we have seen bold acquisitions of biotech-
nology companies by large pharmaceutical companies while
others have made very significant investments to build their in-
house biological drug divisions from scratch. Prominent exam-
ples of merger and acquisition activities related to adopting1046 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltbiotechnology include Genentech by Roche ($46.8B), Imclone
by Eli Lilly ($6.5B), Medarex by Bristol Myers Squibb ($2.4B),
MedImmune by Astra Zeneca ($15.2B), and Wyeth by Pfizer
($68B).
Recombinant protein therapeutics are composed of 20 protei-
nogenic amino acids and metabolized by the same pathways
used by endogenous proteins. Smaller proteins and peptides
are cleared by renal excretion, larger proteins by phagocytic
cells of the reticuloendothelial system. Proteins such as hor-
mones, cytokines, ormAbs show exquisite specificity and some-
times bind their targets with picomolar affinity. To meet the need
of large patient populations, therapeutic biologics are typically
produced by genetically engineered bacteria or higher eukary-
otic cells in large fermenters. Bacteria (e.g., E. coli) are used
for production of nonglycosylated smaller proteins, such as insu-
lin, whereas monoclonal antibodies (mAbs) are in most cases
produced by eukaryotic cell clones (mostly based on Chinese
hamster ovary cells) in order to obtain human-like glycosylation
patterns and to achieve yields in the several grams/liters scale.
Large-scale production of biologics is a highly sophisticated pro-
cess requiring enormous investments in plants, documentation,
and in-process controls.
Protein-based therapeutics can bind targets on the cell sur-
face and in body fluids but are not able to reach intracellular
targets in the cytoplasm or cell nucleus. This is, however, what
small molecule drugs can achieve in addition to binding cell sur-
face receptors and secreted proteins. Typically, small molecule
drugs require a pocket or crevice to specifically and firmly bind
their target and impact its functional activity. Thereby, they are
uniquely suited to inhibit active centers of enzymes, like kinases,
or to block or activate small ligand binding sites of nuclear or
membrane-bound receptors. More challenging is the develop-
ment of small molecule drugs that inhibit the interaction of two
proteins. Small molecule drug development requires careful
evaluation of physical properties and study of metabolism
and pharmacokinetics (PK). These properties can hugely differd All rights reserved
Table 1. Protein-Based Therapeutics Enabled through
Conjugation with PEG
Product Annual Sales $M (2013) Company
Adagen
(Pegademase bovine)
25 Sigma-Tau
Oncaspar
(mPEG-L-asparaginase)
27 Sigma-Tau
Krystexxa (pegloticase) 55 Savient
Pegasys
(peginterferon alfa-2a)
1,400 Roche
PEG-inron
(peginterferon alfa-2b
496 Merck
Cimzia (peg-anti-TNF-a
antibody fragment)
790 UCB
Neulasta (pegfilgrastim) 4,400 Amgen
Mircera
(methoxy polyethylene
glycol-epoetin beta)
467 Roche
Somavert (pegvisomant) 58 Pfizer
Peginesatide (Omontys) N/A N/A
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tissue biodistribution, bioavailability, toxicity, metabolism, and
half-life.
In this perspective, we review a particular aspect of drug
development in which modification of a therapeutic protein
with a chemical compound produces a new molecular entity in
an effort to leverage the best properties of each class. Although
it might seem counterintuitive that combining biologics and small
molecule drugs into one molecule could be of benefit, given the
fundamental differences between them, we describe examples
where resulting small molecule/biologics conjugates exhibit
superior properties. The examples that we will cover include pro-
teins conjugated with biologically inert molecules, such as poly-
ethylene glycol (PEG), to improve their PK properties; antibody
drug conjugates (ADCs) and other proteins conjugated with bio-
logically active small molecules and peptides; and radio immu-
noconjugates, (e.g., proteins conjugated with radio isotopes).
In order to develop these hybrid molecules, chemists and biol-
ogists need to learn how to best work together to solve the prob-
lems inherent in combining these two disparate systems. For
example, most chemical reactions are designed with solvents
and concentration that are not compatible with protein chemistry
(Kalia and Raines, 2010, Stephanopoulis and Francis, 2011). On
the other hand, protein chemistry utilizes immobilization and
enzymatic catalysis that may not be compatible with desired re-
gio- and chemoselective chemical reactions. Despite the fact
that these hybrid therapeutics are still rare, we argue that this
may be an area that could profit from more focused collabora-
tion, exploration, and cross pollination between the fields.
Tuning Proteins and Peptides by Chemical Conjugation
of Polyethylene Glycol
A favorable property of therapeutic proteins—in particular of
mAbs—is their long serum half-life. For instance, the human anti-
body denosumab (Prolia, Amgen) needs to be administered to
women with postmenopausal osteoporosis only every 6 monthsChemistry & Biology 2(Adler andGill, 2011). Most other mAb-based therapies are given
at intervals of 1–4 weeks, which is extremely infrequent com-
pared to daily dosing typical of oral small molecule drugs. Given
their vulnerability to digestion in the gastrointestinal tract, pro-
tein-based therapeutics are injected subcutaneously (s.c.) or
intravenously (i.v.). Subcutaneous administration often employs
devices that improve convenience andmay allow for self-admin-
istration by patients.
The long serumhalf-life of antibodies ismediated by their pino-
cytosis through endothelial cells followed by low-pH binding to
the neonatal FcRn receptor within acidic endosomes, their recy-
cling back to the cell surface, and ultimate release at neutral pH
from FcRn (Zalevsky et al., 2010). One other protein that can use
this highly efficient retention mechanism is human serum albu-
min (HSA), which in humans can circulate in blood for up to
3 weeks (Sleep et al., 2013). Most other serum proteins have
half-lives in the range of hours to just a few days. If the protein
molecular size is below the cut-off for renal clearance (approxi-
mately 50 kDa) serum half-life is only in the range of hours to mi-
nutes. This is the case for many therapeutic peptide hormones
like interferons, insulin, granulocyte colony-stimulating factor
(G-CSF), and interleukin-2 (IL-2), which require daily or multiple
daily injections to ensure sufficient exposure. This situation
was a main reason prompting the search for modifications that
can increase serum half-life of small therapeutic proteins and
peptides, ideally leaving the biological activity of the modified
protein largely unencumbered. This should translate into less
frequent dosing and more convenience for patients.
Polyethylene glycol, or PEG, is a biologically inert, water-solu-
ble polymer with the general formula C2nH4n+2On+1. It is widely
used in pharmaceutical and cosmetic products as well as in
many other industries (Hawley, 2005). Given the well-explored
properties of PEG, it was first selected in the 1970s by Frank Da-
vis and colleagues for conjugation to proteins (Davis, 2002). The
first PEGylated therapeutic protein, Adagen, was approved by
the FDA in 1990. It is an adenosine deaminase inhibitor for treat-
ment of severe combined immunodeficiency disease (Hershfield
et al., 1987). Since then, several other PEGylated protein thera-
peutics followed with market approvals (Harris and Chess,
2003; Kang et al., 2009) (Table 1).
PEGylation of therapeutic proteins and peptides had nu-
merous beneficial effects. By essentially wrapping the conju-
gated protein with a flexible, hydrophilic, and hydrated shell of
PEG, the biophysical properties of proteins can be significantly
altered. For instance, the modification can decrease access of
proteolytic enzymes and of neutralizing antibodies to the protein
core, thereby increasing stability and decreasing immunoge-
nicity at the same time. The Stoke’s radius of the protein is sig-
nificantly increased by conjugated PEG, which reduces renal
clearance and in turn prolongs serum half-life. Proteins that
are hydrophobic or tend to aggregate become more soluble by
PEGylation, further enhancing their stability and bioavailability.
The most predictive and most desired property of conjugated
PEG, however, is its impact on PK by increasing patient expo-
sure or the area under the curve (AUC) of the protein in serum.
From a commercial viewpoint, PEGylation can extend the life cy-
cle and patent life of a therapeutic protein by creation of a novel
drug product. In most cases, PEGylation was found to reduce
the biological activity of the attached protein, presumably1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1047
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Figure 1. Half-Life Extension Technologies
as Applied to GLP-1 Analogs for the
Treatment of Type 2 Diabetes
(A) Structure of Liraglutide (Victoza): lipidation
(palmitoylation) through a glutamic acid spacer on
lysine 26, resulting in HSA binding in vivo and
prolonged half-life (11–15 hr as opposed to 2 min
for endogenous GLP-1 peptide).
(B) Structure of Albiglutide (Eperzan and Tan-
zeum): amino acid exchange (ala8/gly) to reduce
deactivation due to dipeptidyl peptidase-4 and
N-terminal fusion to HSA to extend half-life
(4–7 days).
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desired protein-ligand interaction (Pack and Plu¨ckthun, 1992).
However, increased AUC and higher dosing can compensate
for a reduction in biological activity. Another potential issue of
PEGylation is its metabolism. There seems to be no other
pathway for elimination of the inert polymer than its limited renal
clearance and storage in cellular vacuoles after the attached pro-
tein has been degraded (Rudmann et al., 2013).
The significance of PEGylation is best reflected by the number
of PEGylated therapeutics on the market, impact on patients,
annual sales potential, and the number of companies engaged
in the technology. In 2013, 10 PEGylated drugs made between
US $25M and $4.4B in annual revenues and, in aggregate,
made more than $7.5B of revenues (Table 1). By these numbers,
PEGylation clearly is the most significant and successful chem-
ical modification of therapeutic proteins.
Beyond PEGylation
Recently, attempts have beenmade to replace PEG by recombi-
nantly attaching hydrophilic amino acid sequences that have
PEG-like properties (Schlapschy et al., 2013). These sequences
have either a high content of proline or glycine in order to avoid
formation of stable secondary structures. An obvious advantage
of such recombinant fusions is that they are metabolized as reg-
ular proteins and do not require conjugation chemistry. Another
approach that can be useful for extending serum half-life is the
recombinant fusion of proteins to FcRn-binding Ig Fcg domains.
One very successful example is etanercept (Enbrel, Amgen),
where two copies of the extracellular domain of the human
TNFa receptor are fused to a human Fcg1 domain. Enbrel is
among the top ten best-selling therapeutics. Like PEGylation,
Fcg fusions can significantly change the biophysical properties
of proteins. Fusion proteins must therefore be carefully designed
and optimized for their pharmaceutical behavior.
Other technologies that enable half-life extension of therapeutic
peptides or proteins are based on fusion to HSA, a natural, nonim-1048 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltd All rights reservedmunogenic plasma carrier protein, or to
small molecules that bind to HSA (Subra-
manian et al., 2007). As described above,
HSA uses the same FcRn-based retention
mechanism as antibodies. Lysine, tyro-
sine, and the free thiol residues of HSA
can be used for chemical conjugation to
the drug product, with the free thiol at posi-
tion 34 being most widely used. This
approach is particularly useful for peptideswhere a maleimide linker has been synthetically introduced to
specifically react with the free thiol, allowing for the formation of
a stable thioether bond between albumin and peptide (Dennis
etal., 2002).Alternatively, several smallmoleculesbindwithexcep-
tionally high specificity to HSA and can be tethered to biological
molecules to realize half-life extension, such as conjugation to
the XTEN polymer (Podust et al., 2013). Lipidation or PASylation
(Schlapschy et al., 2013). There are a few commercial applications
of HSA binding that demonstrate the utility of these approaches:
Liraglutide and Albiglutide (Figure 1). Liraglutide is produced by a
process that includes expression of recombinant DNA in
S. cerevisiae and has been engineered to be 97% homologous
tonativehumanGLP-1bysubstitutingarginine for lysineatposition
34. Further chemical processing involves attaching a C-16 fatty
acid (palmitic acid) with a glutamic acid spacer on the remaining
lysine residue at position 26 of the peptide precursor. The lipid
side chain thus introduced binds to albumin and provides
extended half-life. Similar approaches that utilize the inherent lipo-
philicnatureof the therapeuticmolecule includeabraxane, inwhich
the lipophilic taxane small molecule is formulated with HSA. Albi-
glutide is a GLP-1 receptor agonist developed through the fusion
of two repeats of human GLP-1 (7–36) molecules to recombinant
human albumin. The GLP-1 dimer was used to avoid potential re-
ductions of the interaction of the GLP-1 moiety of the monomer
with its receptor in the presence of albumin. A single amino acid
substitution (ala8/gly) renders the molecule resistant to dipep-
tidyl peptidase-4 (DPP-4). Albiglutide has a half-life of 4–7 days,
much longer than other synthetic GLP-1 molecules, such as ex-
enatide (Byetta) and liraglutide (Victoza). The utility of HSA binding
as a mechanism for tuning pharmacokinetic properties of peptidic
moleculeshasshownutility in the lab,clinic,andnow in thepractice
of medicine and holds great promise for future applications.
Future Technologies: Native Chemical Ligation and
Expressed Protein Ligation
Native chemical ligation (Dawson et al., 1994) and expressed pro-
tein ligation (Shah and Muir, 2014) are two techniques that
AB
Figure 2. Mechanisms of Peptide and Protein Splicing
(A) Native chemical ligation that involves N-terminal cysteine trans-thioesterification followed by N-S rearrangement to form a new peptidic bond and (B)
expressed protein ligation catalyzed by an intein subunit to facilitate S-N rearrangement followed by capture and succinimide formation. The capture of the
thioester can be within the same protein or between an exogenously introduced N-terminal cysteine containing peptide, resulting in protein fusion products.
Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1049
Chemistry & Biology
Perspective
AB
C
D
Figure 3. Examples of Antibody Drug
Conjugate Technology Indicating Warhead,
Linker Type, and Method of Conjugation
to mAb
(A) Mylotarg (gemtuzumab ozogamicin): cal-
icheamicin warhead, cleavable (disulfide) linker,
lysine conjugation (2–3 per IgG) to a mAb to CD33.
(B) Kadcyla (ado-trastuzumab emtansine): may-
tansine warhead (Dm-1), noncleavable linker
(thioether), lysine conjugation (3–4 per igG) to amb
that taregts HER2.
(C) Adcetris (Brentuximab vedotin: auristatin
warhead (MMAE), capthesin cleavable linker,
cysteine conjugation (3–5 per IgG) to a mAb that
targets CD30.
(D) Ambrx: next-generation ADC technology plat-
form whereby a HER2-specific mAb is site-spe-
cifically conjugated to a potent cytotoxic tubulin
inhibitor. Site specificity is achieved through
incorporation of p-Ac Phe to enable orthogonal
chemical reactivity and site-directed conjugation.
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and protein expression and have recently been advanced by
Kent,Muir, and colleagues (Shah andMuir, 2014). In native chem-
ical ligation, an N-terminal cysteine residue reacts with a thioester
to undergo transthioesterification followed by a rapid S/N acyl
transfer to form a new amide bond (Figure 2). This reaction is a
powerful tool for peptide ligation and hence protein synthesis.
Expressed protein ligation is an extension of native chemical
ligation that couples the power of peptide synthesis with protein
expression. In this method, a target protein is expressed as a
fusion protein with an intein, a protein subunit that posttransla-1050 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltd All rights reservedtionally generates a thioester at the C ter-
minus of the target protein. The intein
fusion proteins are treated with peptides
containing an N-terminal cysteine resi-
due to effect native chemical ligation.
The resulting product is a chemical
conjugation of an expressed protein,
although it is not evident by initial inspec-
tion because the ‘‘conjugate’’ is a pep-
tide itself. The fusion is termed ‘‘trace-
less’’ because it incorporates protein
fusion without any nonpeptidic reagents
or linkers. The intermediate thio-ester
can be trapped in trans by an exogenous
synthetic peptide to create a new fusion
protein. This very powerful tool has
been utilized to make new biologically
active fusion proteins and therapeutic
agents. Future applications include
utilizing these methods for ‘‘Biologics
Structure Activity Relationship,’’ which
brings the insight of modern medicinal
chemistry into the arena of biologics
drug discovery (Fierz and Muir, 2012).
Chemical Conjugation of Toxins to
Antibodies for Tumor Targeting
Chemotherapy of cancer often uses high-
ly toxic, small molecule compounds withnarrow therapeutic windows. One important class of chemother-
apies targets tubulin, a component of the mitotic spindle. The
issue with this class, as with a number of other available chemo-
therapeutic compounds, is their lack of specificity, as they affect
both proliferating cancer and normal cells, leading to, among
many other side effects, hair loss (alopecia), neurotoxicity,
gastrointestinal bleeding, and/or immunodeficiency from bone
marrow suppression. As mentioned above, mAbs can bind to
cell surface antigens on cancer cells with high specificity and af-
finity. This prompted the idea to use monoclonal antibodies as a
vehicle to precisely deliver highly toxic compounds to cancer
Drug1 on HC Drug1 
DAR 
Drug2 on LC Drug2 DAR Total DAR 
MMAF 1.8 SN-38 1.4 3.2 
MMAF 1.8 PBD dimer 1.5 3.4 
MMAF 1.9 Gemcitabie 1.6 3.6 
PBD dimer 1.9 MMAF 1.7 3.7 
Gemcitabine 2.0 MMAF 1.6 3.5 
A
B
Figure 4. Emerging Technologies for Antibody Drug Conjugates
(A) Sutro Xpress CF technology can incorporate nonnatural amino acids (nnAA) in an antibody structure, thereby allowing for single-species ADCs with site-
specific conjugation of linker and warhead. Additionally, multiple different warheads can be conjugated to a single antibody as is exemplified in the table.
(B) Mersana Fleximer technology allows multiple warheads (>20) to be conjugated on a polyal framework.
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while reducing dose levels and side effects (Chari et al., 2014).
Quite a number of challenges had to be overcome on the 30
year path to the first commercial antibody drug conjugate
(ADC) products. The efforts necessitated identification of ideal
toxins to couple to antibodies; selection of the right antibodies
targeting the most appropriate antigens; design of mAb/toxin
linkers with ideal properties; optimization of chemical strategy
to covalently attach small molecule toxins to the chosen anti-
body in a directed, efficient, stable and reproducible fashion;
and controlling the release of the toxin from the ADC once it is
delivered to the target cell.
While an enormous number of ADC programs are in preclin-
ical and clinical development, only three ADCs have thus farChemistry & Biology 2reached clinical routine. One of them, for treatment of acute
myelogenous leukemia in elderly patients, gentuzumab ozoga-
micin (Mylotarg, Pfizer; Sorokin, 2000), has been already re-
tracted from the market because of a questionable risk/benefit
ratio. The other two, brentuximab vedotin (Adcetris, Seattle Ge-
netics) and ado-trastuzumab emtansine (Kadcyla or T-DM1,
Roche), which were only recently approved by the FDA,
showed high clinical activity in the treatment of Hodgkin’s
lymphoma (HL) and metastatic breast cancer, respectively.
Adcetris’ approval was based on a phase II clinical trial
showing a response rate of >90% in refractory HL (Vaklavas
and Forero-Torres, 2012). Kadcyla showed clinical responses
and an increased overall survival in metastatic breast cancer
patients who became refractory to the humanized anti-HER-21, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1051
Table 2. Companies Engaged in Developing ADC Technologies and Clinical Candidates
Company Linker Technology Warhead Examples
Wyeth/Pfizer disulfide cleavable linker calicheamycin gentuzumab ozogamicin, Inotuzumab
ozogamicin (CMC-544; Mylotarg)
Immunogen noncleavable maleimide thio
Michael conjugation
maytansine ado-trastuzumab emtansine
(T-DM1 Kadcyla);
lorvotuzumab mertansine (CD56,
IMGN-901), SAR3419 (CD19)
Seattle
Genetics
noncleavable maleimide thio
Michael conjugation
auristatin (MMAE or MMAF) Adcetris (CD30) CD22-specific
CD79b-specific;
GPNMB specific;
PSMA specific linked to MMAE or MMAF
Sutro cell-free expression of mAbs with
nonnatural amino acids (nnAAs)
dual warhead conjugates Celgene and Pfizer collaborations
Ambryx EuCode expression system for nnAAs multiple warheads (FK 506) Astellas, BMS, Merck partnerships
Mersana flexible linker technology multiple
Spirogen pyrrolobenzodiazepine (PBD) technology PDB purchased by AZ in 2013
PolyTherics ThioBridge technology cytolysins IPO launched in June 2014
CytomX probody drug conjugates maytansine Pfizer collaboration
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mAb backbone of the ADC (LoRusso et al., 2011).
Mylotarg, Adcetris, and Kadcyla use different strategies to
chemically conjugate small molecule warheads to their respec-
tive antibody backbone. Mylotarg uses a cleavable linker to
attach calicheamycin, a DNA double-strand breaking toxin, to
an anti-CD33 monoclonal antibody. Adcetris uses a capthesin-
cleavable linker to tether auristatin, a microtubule assembly in-
hibitor, to an anti-CD30 monoclonal antibody. Lastly, Kadcyla
uses a noncleavable linker to attach maytansine, likewise a
microtubule inhibitor, to the therapeutic anti-HER-2 antibody
trastuzumab. Ambrx has taken the very bold approach of ex-
panding the genetic code to allow the incorporation of the
nonnatural amino acid p-acetyl-phenylalanine. This provides a
ketone functionality within a peptidic network that has orthoga-
nol reactivity and allows for highly selective and precise conjuga-
tion (Figure 3).
Preclinical models showed that small molecule payloads that
were too toxic when administered on their own were tolerated
and highly efficacious in tumor eradication when bound to a tu-
mor-targeting monoclonal antibody (Junutula et al., 2008).
Because only a minute fraction of administered ADCs will reach
and bind tumor cells, the bulk of administered ADC needs to be
tolerated andmetabolized by normal tissues. This leads to dose-
limiting off-target toxicities of ADCs including hepatotoxicity and
bone marrow suppression. In addition, on-target toxicities are
possible if normal tissues express the antibody’s target antigen
(McDonagh et al., 2008).
Based on two marketed products and multiple clinical pro-
grams, ADCs can be considered a valuable and successful class
of drug products where biologics and chemicals are combined in
a synergistic fashion. What will be decisive for the development
of future and further improved ADCs is the choice of target anti-
gens, choice of the most adequate linker chemistry, and a better
defined and controlled attachment of toxins to the antibody
(Jackson et al., 2014). Site-directed incorporation of unnatural
amino acids has recently been shown to allow for an exquisitely1052 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltdirected conjugation of toxins to antibodies (Axup et al., 2012).
The resulting ADCs were found to be more potent and differen-
tiate themselves from molecules generated through random
attachment to reactive natural amino acids (Tian et al., 2014;
Flemming 2014). Others have focused on the covalent attach-
ment of multiple different toxins to a single mAb, providing an
orthogonal mechanism for cellular apoptosis. In addition, the
company Mersana has recently demonstrated the feasibility of
a multivalent tether that allows for significantly increasing the
number of toxins attached per antibody (Papisov et al., 2005)
(Figure 4). Currently, enormous efforts are ongoing in the industry
to provide new ADC technologies and product candidates for
cancer patients (Table 2).
Chelation of Radioisotopes to Antibodies for the
Treatment of Cancer
Another variation of ADCs is radioimmunoconjugates (RICs).
Here, the toxic payload is a radioactive isotope, like the beta
emitters 131-iodine or 90-yttrium, that is typically attached to a
chelating compound that is chemically conjugated to an anti-
body. This technology has also been used to produce diagnostic
imaging reagents some time before the first RICs were devel-
oped for therapeutic use. Radioactively labeled antibodies allow
the imaging of tumors expressing the respective target antigen of
the antibody. The only two therapeutic RICs have been commer-
cialized: Zevalin and Bexxar, both of which target the B cell an-
tigen CD20 for the treatment of patients with non-Hodgkin lym-
phoma (NHL) (Figure 5).
Radiolabeledmonoclonal antibodies have also been usedwith
encouraging results in conjunction with stem cell transplantation
in patients with hematologic malignancies targeting a variety of
surface antigens including CD33, CD45, and CD66 for leuke-
mias; CD20 and CD22 for non-Hodgkin’s lymphomas; and
ferritin for Hodgkin’s disease (Pagel et al., 2002). Further work
in this area has resulted in the emergence of ‘‘theragnostics,’’
molecules that can be leveraged as diagnostics as well as ther-
apeutics. In addition, utilizing these platforms as part of gold andd All rights reserved
A B Figure 5. Representative Structure
Radioimmunoconugates
(A) 90Y Ibritumomab tiuxetan (Zevalin) thiourea
linker DPTA chelating ligand for 90Y conjugated
via lysine to a mAb targeted to CD20.
(B) 131I-tositumab (Bexxar) iodinated tyrosine
radioactive warhead in a mAb targeted to CD20.
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for diagnosing and treating deadly cancers such as glioblastoma
(Setua et al., 2014). Further exploration of this area should pro-
vide useful extensions of this technology.
Conclusions
Here we described a number of important human therapeutics
that depends on the successful and synergistic combination of
chemistry and biology. These combinations were greatly aided
by the development of tailored coupling chemistries, an intelli-
gent selection of both chemical entities and proteins and—as
seems notorious in drug development—an enormous trial and
error effort that lasted for decades. Just the few existing exam-
ples of successful combinations should inspire us to more
systematicly look at our pharmaceutical and biotechnology in-
dustries from the perspective of combining the small molecule
space with the protein universe. We think the opportunities
that await in this area are substantial and that investing efforts
to combine biologics and small molecules and solve their individ-
ual shortcomings will be fruitful and worthwhile from both a com-
mercial and a clinical perspective.
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